Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Chronic Coronary Syndrome (CCS)
Published: 03 October 2022
-
Views:
24713
-
Likes:
7
-
Views:
24713
-
Likes:
7
-
Up Next
-
9m 52sPart 5 Q&A and Discussion
-
12m 29sPart 1 Unmet Needs in CCS Marc P Bonaca, Philippe Gabriel Steg, Deepak L Bhatt
-
16m 52sPart 2 Risk Mitigation in High and Very High-Risk Patients: What Does the Data Say? Philippe Gabriel Steg
-
15m 51sPart 3 Prevention in Diabetes Deepak L Bhatt
Overview
This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.
The second broadcast in this series, focused on Chronic Coronary Syndrome (CCS). In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.
Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, FR) chairs the proceedings, and is joined by Dr Marc Bonaca (University of Colorado School of Medicine, US) and Dr Deepak Bhatt (Brigham and Women's Hospital, US) for a series of insightful presentations and discussions.
Catch up now on the other broadcasts in this series:
Key Learning Objectives
Following the completion of this programme, physicians will be in a position to:
- Discuss the disease burden in both primary and secondary prevention patients with high-risk features
- Identify clinical features that make CCS patients high risk
- Choose an appropriate antiplatelet regimen for CCS patients based on relevant history and current risk profile
- Recall the results of RCTs using potent P2Y12 inhibitors in CCS patients with a prior MI and in patients with existing diabetes, with/without MI
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Nurses and any other allied HCPs
More from this programme
Part 1
Unmet Needs in CCS
| 1 session | |
| Unmet Needs in CCS | Watch now |
Part 2
Risk Mitigation in High and Very High-Risk Patients: What Does the Data Say?
Part 3
Prevention in Diabetes
| 1 session | |
| Prevention in Diabetes | Watch now |
Part 4
Long-term Management of CCS
| 1 session | |
| Long-term Management of CCS | Watch now |
Part 5
Q&A and Discussion
| 1 session | |
| Q&A and Discussion | Watch now |
Faculty Biographies
Marc P Bonaca
Director of Vascular Research and an Associate Professor of Medicine
Dr Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health which is an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. CPC is a core resource of the University of Colorado research and community outreach infrastructure.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. Following his medical residency training, he served as a Cardiology Fellow at Brigham and Women’s Hospital and subsequently completed a…